GlassScriptPhysician profile
Mary A Giddens
NPI 1669414025
$4,820.43
in general payments reported to CMS, 2019-2025
34 companies · $638 in 2025
The $638 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $272 · 2021: $803 · 2022: $850 · 2023: $1,199 · 2024: $699 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $691.64 | 2019-2025 | |
| Novo Nordisk INC | $578.33 | 2021-2025 | Wegovy, Saxenda |
| Astellas Pharma US INC | $434.15 | 2020-2025 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $375.43 | 2023-2025 | Accrufer |
| Daiichi Sankyo INC. | $299.19 | 2020-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $269.89 | 2019-2025 | |
| Exeltis, USA INC. | $229.50 | 2019-2025 | Slynd |
| Amgen INC. | $226.65 | 2023-2025 | Evenity, Prolia |
| Pfizer INC. | $222.22 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $197.82 | 2023-2025 | Myfembree |
| Channel Medsystems, INC. | $176.43 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $156.05 | 2021-2025 | |
| Aspira Women'S Health INC | $94.02 | 2023-2024 | Ova1 |
| Hologic Sales and Service, LLC | $79.12 | 2021-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Scynexis, INC. | $79.08 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $74.67 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $70.48 | 2022 | |
| Glaxosmithkline, LLC. | $61.45 | 2021 | |
| Therapeuticsmd, INC. | $49.47 | 2019-2021 | |
| Organon LLC | $47.38 | 2022-2025 | Jada System |
| Pacira Pharmaceuticals Incorporated | $46.39 | 2023-2024 | Exparel |
| Avion Pharmaceuticals | $41.31 | 2019-2022 | |
| Duchesnay USA Incorporated | $39.26 | 2019-2020 | |
| Lupin INC. | $38.11 | 2020-2021 | |
| Becton, Dickinson and Company | $36.04 | 2021 | |
| Millicent US INC | $34.71 | 2025 | Intrarosa, Femring |
| Merck Sharp & Dohme LLC | $31.83 | 2023-2024 | Gardasil 9, Gardasil |
| Mylan Pharmaceuticals INC. | $27.73 | 2021 | |
| Boston Scientific Corporation | $26.41 | 2019 | |
| Coopersurgical, INC. | $24.91 | 2020-2022 | |
| Convatec INC. | $17.55 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.79 | 2019 | |
| Evofem Biosciences, INC. | $13.72 | 2021 | |
| Agile Therapeutics, INC. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Giddens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.